글로벌 Zellweger 스펙트럼 장애 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

Zellweger 스펙트럼 장애 시장 분석

젤위거 스펙트럼 장애(ZSD)는 인체의 대부분 장기에 영향을 미치는 유전성 상염색체 유전 질환의 그룹입니다. 이 장애는 PEX 유전자라고 알려진 특정 유전자의 돌연변이로 인해 발생하며, 이로 인해 결함이 생깁니다. 높은 이마, 근육 근력 저하, 발작, 시력 및 청력 장애와 같은 ZSD의 초기 징후는 일반적으로 출생 직후에 나타납니다. 따라서 유전체학 연구에 대한 관심이 높아지는 것은 ZSD 시장을 활성화하는 데 중요한 요인입니다. 펙신(PEX)이라고 하는 과산화물 생물 발생에 관여하는 다양한 유전자의 돌연변이는 ZSD로 이어지고 과산화물 조립 및 기능을 방해합니다. ZSD 환자의 약 60%는 이형성 PEX1 돌연변이를 가지고 있으며, 현재까지 약 90개의 고유한 PEX1 돌연변이가 확인되었습니다. 젤위거 스펙트럼 장애는 광범위한 증상을 보이는 상염색체 열성 장애입니다.

Zellweger 스펙트럼 장애 시장 규모

글로벌 Zellweger 스펙트럼 장애 시장 규모는 2023년에 1억 8,196만 달러로 평가되었으며, 2031년까지 3억 5,518만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 8.72%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

Zellweger Spectrum Disorders Market Definition

Zellweger spectrum disorders (ZSDs) are a group of rare, genetic, metabolic disorders characterized by the dysfunction of peroxisomes, cellular structures responsible for various metabolic processes. These disorders are caused by mutations in genes involved in peroxisome biogenesis and function. ZSDs are inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the disorder. Symptoms of ZSDs can include developmental delays, neurological abnormalities, liver dysfunction, and facial dysmorphism. There is currently no cure for ZSDs, and treatment focuses on managing symptoms and providing supportive care.       

Zellweger Spectrum Disorders Market Dynamics

Drivers

• Increasing Prevalence of Genetic Disorders 

The growing prevalence of genetic disorders, including Zellweger spectrum disorders (ZSDs), improved awareness and diagnostic capabilities have led to more cases being identified, increasing the demand for treatment options. This is expected to continue as genetic testing becomes more accessible and healthcare professionals become more adept at recognizing and diagnosing these disorders. As a result, there is a growing need for effective therapies and management strategies for ZSDs, driving market growth.     

• Advancements in Genomics Research 

Researchers are making significant strides in understanding the genetic basis of ZSDs, including the identification of novel genetic mutations associated with the disorder. This deeper understanding is leading to the development of targeted therapies that aim to address the underlying genetic causes of ZSDs. Additionally, advancements in genomics research are improving the accuracy and efficiency of diagnostic tests for ZSDs, enabling earlier and more accurate diagnosis, which is essential for effective treatment. Overall, these advancements in genomics research are driving innovation in the field of ZSDs, offering new hope for patients and driving market growth.

Opportunities

• Expansion of Genetic Testing Services 

Genetic testing allows for the early detection of ZSDs, enabling healthcare providers to intervene sooner and provide more effective treatments. Additionally, genetic testing can provide valuable information for family planning, helping individuals make more informed decisions about their reproductive choices. As genetic testing becomes more accessible and affordable, the demand for these services is expected to increase. The expansion of genetic testing services, including prenatal testing and carrier screening, presents a significant opportunity for market growth.  

• Patient Advocacy and Support Groups   

Patient advocacy and support groups are instrumental in raising awareness about Zellweger spectrum disorders (ZSDs) and providing support to patients and their families. These groups play a crucial role in driving market growth by advocating for research funding, promoting early diagnosis and intervention, and improving access to care. Additionally, patient advocacy groups can provide valuable insights into the needs and preferences of patients, helping to guide the development of new treatments and services. By working closely with healthcare providers, policymakers, and the broader community, patient advocacy, and support groups can help drive innovation and improve outcomes for individuals affected by ZSDs.

Restraints/Challenges

• Lack of Standardized Treatment Guidelines 

Without clear guidelines, healthcare providers may be hesitant to adopt new treatments or approaches, leading to variability in patient care. This lack of standardization can hinder market growth by creating uncertainty among healthcare providers and reducing confidence in new therapies or diagnostic tools. The absence of standardized treatment guidelines for Zellweger spectrum disorders (ZSDs) presents a challenge in providing consistent care and achieving optimal outcomes for patients.  

• Limited Availability of Specialized Healthcare Services 

Specialized healthcare services for Zellweger spectrum disorders (ZSDs), such as genetic counseling, specialized clinics, and multidisciplinary care teams, are essential for providing comprehensive care to individuals with ZSDs, including accurate diagnosis, personalized treatment plans, and ongoing support. The lack of access to these specialized services can result in delayed diagnosis, inadequate treatment, and poor health outcomes for patients. The limited availability of specialized healthcare services poses a significant barrier to effective management of the disorder.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Zellweger Spectrum Disorders Market Scope

The market is segmented on the basis of therapy, type, diagnosis, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Heimler Syndrome
• Infantile Refsum Disease
• Neonatal Adrenoleukodystrophy
• Zellweger Syndrome

Therapy

• Pediatricians
• Neurologists
• Surgeons
• Audiologists
• Ophthalmologists
• Orthopedists

Diagnosis

• Blood Test
• Urine Test
• Ultrasound,
• Genetic Test

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Zellweger Spectrum Disorders Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, source, type, drugs, application, route of administration, end-user and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to rising research and development endeavors, advancements in diagnostics, increased initiatives for screening newborns, enhanced collaborations, and heightened awareness.          

아시아 태평양 지역은 첨단 연구 활동, 잘 확립된 의료 인프라, 신생아 의무 ​​검진, 지역 내 건강 인식 향상으로 인해 상당한 성장을 보일 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

Zellweger 스펙트럼 장애 시장 점유율

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 센토진 NV(독일)
• 호프만-라 로슈 유한회사(스위스)
• 퍼킨엘머 주식회사(미국)
• Bio-Rad Laboratories, Inc. (미국)
• 바이오마린(미국)
• 사렙타 테라퓨틱스(미국)
• 지멘스 헬스케어 GmbH (미국)
• Blueprint Genetics Oy(핀란드)
• 제너럴 일렉트릭(미국)
• Koninklijke Philips NV(네덜란드)
• 히타치 주식회사(일본),
• GeneDx, LLC(미국)
• Asper Biogene LLC(에스토니아)

SKU-64014